Series: Landmark Trials in Endocrinology & Metabolism | Study #5
Category: SGLT2 Inhibitors · Heart Failure | Design: Multicentre, double-blind, placebo-controlled RCT | n: 4,744 | Follow-up: 18.2 months (median)
📋 Summary
Authors: McMurray JJV et al., for the DAPA-HF Trial Committees and Investigators
Journal: N Engl J Med 2019;381:1995–2008 | DOI: 10.1056/NEJMoa1911303
DAPA-HF enrolled 4,744 patients with symptomatic heart failure and reduced ejection fraction (NYHA class II–IV, left ventricular ejection fraction 40% or less), of whom 45.4% had type 2 diabetes mellitus. Patients were randomly assigned to dapagliflozin 10 mg once daily or placebo on a background of optimised guideline-directed medical therapy. The primary composite outcome comprised worsening heart failure, defined as either hospitalisation or an urgent outpatient visit requiring intravenous therapy, or cardiovascular death. Over a median follow-up of 18.2 months, the primary outcome occurred in 16.3% of patients in the dapagliflozin group and 21.2% in the placebo group (HR 0.74; 95% CI 0.65 to 0.85; p<0.001), representing a 26% relative risk reduction. The individual components were each reduced: cardiovascular death (HR 0.82; 95% CI 0.69 to 0.98), worsening heart failure (HR 0.70; 95% CI 0.59 to 0.83), and all-cause mortality (HR 0.83; 95% CI 0.71 to 0.97). Critically, the magnitude of benefit was consistent across the pre-specified subgroups of patients with and without type 2 diabetes at baseline, establishing that the therapeutic benefit of SGLT2 inhibition in heart failure is independent of the glucose-lowering mechanism that originally defined the drug class.
📊 Key Findings
| Outcome | Dapagliflozin | Placebo | Effect Size |
|---|---|---|---|
| Primary composite (worsening HF or CV death) | 16.3% | 21.2% | HR 0.74 (0.65–0.85) · p<0.001 · 26% RRR |
| Worsening HF (hospitalisation or urgent visit) | — | — | HR 0.70 (0.59–0.83) |
| Cardiovascular death | — | — | HR 0.82 (0.69–0.98) |
| All-cause mortality | — | — | HR 0.83 (0.71–0.97) |
| Benefit in T2DM subgroup | Consistent with overall | HR 0.75 (0.63–0.90) | |
| Benefit in non-T2DM subgroup | Consistent with overall | HR 0.73 (0.60–0.88) | |
| Absolute risk reduction (primary composite) | ~4.9% over 18.2 months | NNT approximately 21 | |
💬 Expert Commentary
DAPA-HF was the pivotal trial that formally decoupled the heart failure benefit of SGLT2 inhibition from any requirement for type 2 diabetes. The cardiovascular outcomes trials that preceded it, principally EMPA-REG OUTCOME and CANVAS, had enrolled patients with diabetes by design and reported heart failure hospitalisation reductions as secondary endpoints in populations not specifically selected for heart failure. DAPA-HF enrolled patients on the basis of a confirmed heart failure diagnosis with reduced ejection fraction and designed the primary endpoint around heart failure deterioration events. The finding that the treatment effect was homogeneous across the diabetes and non-diabetes subgroups was not merely a positive test of interaction statistics. It signified that the mechanism responsible for the heart failure benefit of dapagliflozin does not depend on glucose transport inhibition in the kidney and is instead operating through pathways more directly relevant to myocardial function, including haemodynamic offloading, reduction in cardiac preload and afterload through natriuresis and osmotic diuresis, attenuation of myocardial inflammation, and possibly direct effects on myocardial energetics through ketone body utilisation. This mechanistic inference, well-supported by preclinical and translational data, was formally confirmed in a powered clinical trial for the first time by DAPA-HF.
The absolute risk reduction of approximately 4.9% over 18 months, corresponding to an NNT of around 21, is substantially more favourable than the NNTs observed in the SGLT2 inhibitor cardiovascular outcomes trials, which is expected given the higher baseline event rate in an established heart failure population. The significant reduction in all-cause mortality, which reached conventional significance at HR 0.83 (0.71–0.97), is particularly important as mortality signal in heart failure trials is the most demanding regulatory and clinical benchmark. The cardiovascular death HR of 0.82 was individually significant, reinforcing that the benefit extends beyond preventing repeat hospitalisation and includes genuine survival gain. DAPA-HF, together with EMPEROR-Reduced, was the evidence base for the class inclusion of SGLT2 inhibitors in the foundational quadruple therapy framework for HFrEF within international cardiology guidelines.
Limitations: The median follow-up of 18.2 months is relatively brief in the context of a chronic progressive condition like heart failure, and long-term mortality effects cannot be fully assessed. The trial enrolled patients with ejection fraction 40% or less, and efficacy in heart failure with mildly reduced or preserved ejection fraction was not addressed. The study was industry-sponsored by AstraZeneca.
🔑 BOTTOM LINE
DAPA-HF demonstrated that dapagliflozin reduced worsening heart failure and cardiovascular death by 26% in patients with HFrEF, with identical benefit regardless of diabetes status, establishing SGLT2 inhibition as a core component of quadruple therapy for heart failure with reduced ejection fraction and defining the class as a cardiovascular drug rather than solely an antidiabetic one.
⭐ Clinical Impact Rating: ●●●●● Practice-defining
Next in the series: Study #6 EMPEROR-Reduced: Empagliflozin Outcomes in Chronic Heart Failure with Reduced Ejection Fraction
